Findings lay groundwork for human clinical trial planned for August 2016
A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it. Over one million men and women are living with colorectal cancer in the United States. The National Cancer Institute estimates 4.5% of all men and women will be diagnosed with the cancer during their lifetime, making it the third most common non-skin cancer.
In the study published online in Nature Communications, researchers showed how certain colorectal cancer cells reprogram their metabolism using glutamine, a non-essential amino acid. Many cancer cells rely on glutamine to survive. How they become so dependent on the molecule is hotly debated in the field.
Researchers studied a subset of colorectal cancer cells containing a genetic mutation called PIK3CA. This mutation is located in a gene critical for cell division and movement, and is found in approximately one third of all colorectal cancers. The mutation is also the most commonly identified genetic mutation across all cancers, making the results of the study universally appealing.
Researchers were interested in determining whether or not the common PIK3CA mutation contributes to changes in cancer cell metabolism, such as how nutrients like glutamine are processed. Normally, glutamine is broken down by cancer cells into several other molecules with the help of specific enzymes. This complicated system helps produce adenosine triphosphate, the energy currency of all cells, and other molecules critical for colorectal cancer cell growth.
The researchers found that colorectal cells with the PIK3CA mutation broke down significantly more glutamine than cells without the mutation. The researchers identified several enzymes involved in the process that are more active in the mutant cancer cells than in other cell types, explaining the increased need for glutamine. These enzymes become overactive in the mutant cancer cells due to a cascade of signals led by the protein encoded by mutant PIK3CA gene. This finding represents a novel and important link between the common PIK3CA mutation and altered glutamine metabolism in cancer cells.
Zhenghe John Wang, PhD, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University School of Medicine helped lead the study. “In layman’s terms, we discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs.”
When the researchers lowered the amount of glutamine available to mutant cancer cells growing in laboratory dishes, the cancer cells died. This discovery led the team to investigate the effects of blocking glutamine availability in mice with colorectal cancer tumors containing the common PIK3CA mutation. Wang and colleagues found that exposing these mice to a compound that blocks glutamine metabolism consistently suppressed tumor growth. They did not observe the same effect on tumors without the mutation. Together, these results provide a promising new therapeutic avenue to suppress growth of colorectal tumors with the PIK3CA mutation. The researchers have filed a patent application based on the unique mechanism of tumor suppression they have identified and the work is available for licensing.
“This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center,” according to Neal Meropol, MD, Dr. Lester E. Coleman, Jr. Professor of Cancer Research and Therapeutics, chief of the division of hematology and oncology, and principal investigator for the trial. The phase I/II study will test the effects of a glutamine metabolism inhibitor in patients with advanced colorectal tumors.
The Latest on: Colorectal cancers
via Google News
The Latest on: Colorectal cancers
- A bug in the gut that shoots up risk of colon canceron February 3, 2020 at 5:13 am
Indian researchers have identified a new gut-inhabiting bacterium that increases the risk of colon cancer 1. This bacterium can break down chemicals with anticancer properties called flavonoids, which ...
- Tulane, LSU researchers say earlier screenings could help detect colorectal canceron January 31, 2020 at 2:20 pm
Colorectal cancer has typically been a disease associated with aging. And in years past, medical groups did not recommend screening for the disease until age 50. But the reason colon cancer isn’t as ...
- More Fuel for the Colon Cancer Screening Age Debateon January 31, 2020 at 1:34 pm
Analysis of colorectal cancer (CRC) incidence by age in the U.S. revealed a spike right when screening is recommended to begin, indicating that many latent tumors go undiagnosed ahead of routine ...
- Earlier screening for colon cancer may catch cases earlieron January 31, 2020 at 8:47 am
The analysis of colon and rectal cancer rates among adults in the United States found there is a 46 percent increase in new diagnoses from ages 49 to 50, an indication that latent cases are perhaps ...
- Spike in colorectal cancer from age 49 to 50 suggests many undiagnosed before screeningson January 31, 2020 at 8:04 am
A year-by-year age analysis of colorectal cancer rates among U.S. adults finds a 46% increase in new diagnoses from ages 49 to 50, indicating that many latent cases of the disease are likely going ...
- Novel nano-vehicle for delivery and efficiency of anticancer auraptene against colon cancer cellson January 31, 2020 at 2:23 am
The aim of this study is to devise, prepare and characterize nano encapsulated auraptene (AUR) and evaluate cytotoxic and apoptotic effects on HT-29 colon cancer cells. Herein, AUR nano formulations ...
- John Andretti, NASCAR Driver, Dead at 56 Following Colon Cancer Battleon January 30, 2020 at 5:13 pm
The NASCAR and IndyCar driver has died after a battle with colon cancer, Andretti Autosport announced on Thursday. He was 56. “It [is] with the heaviest of hearts we share that John Andretti has ...
- Professional race car driver John Andretti dies at 56 after a long battle with colon canceron January 30, 2020 at 4:06 pm
NASCAR, IndyCar and sports-car racing competitor John Andretti died on Thursday at the age of 56 after a long battle with colon cancer. The Andretti Autosport team confirmed the news. His family ...
- John Andretti, NASCAR driver and nephew of Mario Andretti, dies from colon canceron January 30, 2020 at 1:34 pm
NASCAR driver John Andretti, a nephew of racing legend Mario Andretti, has died from colon cancer, according to a tweet from Andretti Autosport.
- John Andretti, nephew of Mario, dies after battle with colon canceron January 30, 2020 at 1:03 pm
Longtime race car driver John Andretti died Thursday after a battle with colon cancer. He was 56. A native of Bethlehem, Pennsylvania and graduate of Moravian College, Andretti was the nephew of Mario ...
via Bing News